SNDX-5613

DRUG3 trials

Sponsors

Syndax Pharmaceuticals Inc., M.D. Anderson Cancer Center, Syndax Pharmaceuticals

Conditions

Acute Myeloid LeukemiaAcute Myeloid LeukemiasRelapsed or Refractory Acute Leukemias

Phase 1

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

RecruitingNCT05360160

M.D. Anderson Cancer CenterAcute Myeloid Leukemia

Start: 2022-10-14End: 2026-12-01Target: 43Updated: 2025-10-23

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

RecruitingNCT06226571

Syndax PharmaceuticalsAcute Myeloid Leukemias

Start: 2024-05-21End: 2027-02-01Target: 76Updated: 2026-02-17

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation.

Active, not recruitingCTIS2024-513759-34-00

Syndax Pharmaceuticals Inc.Relapsed or Refractory Acute Leukemias

Start: 2022-05-31Target: 34Updated: 2025-08-19

Related Papers

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Blood2025-11-031 citations

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Blood2025-11-031 citations

Post-transplant maintenance with revumenib in children with HOX-driven AML

Blood2025-11-03

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood2024-11-0534 citations

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Blood2023-11-0243 citations